This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
This antibody is peptide affinity purified using peptides CEPRGLS(M)KQIRFRFG (positive selection) and CEPRGLS(V)KQIRFRFG (negative selection).
Ubiquitin-like protein which can be covalently attached to target lysines as a monomer. Does not seem to be involved in protein degradation and may modulate protein subcellular localization, stability or activity. Upon oxidative stress, conjugates to various anti-oxidant enzymes, chaperones, and stress defense proteins. May also conjugate to NFKBIA, TFAP2A and FOS, negatively regulating their transcriptional activity, and to NR3C1, positively regulating its transcriptional activity. Covalent attachment to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I.
Expressed mainly in adult and embryonic kidney. Expressed at various levels in immune tissues, with the highest expression in the lymph node and spleen.
Belongs to the ubiquitin family. SUMO subfamily. Contains 1 ubiquitin-like domain.
In contrast to SUMO1, SUMO2 and SUMO3, seems to be insensitive to sentrin-specific proteases due to the presence of Pro-90. This may impair processing to mature form and conjugation to substrates.
Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human breast carcinoma tissue, labeling SUMO4 using ab170850 at a 1/50 dilution, followed by peroxidase-conjugation of the secondary antibody and AEC staining.
Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human hepatocarcinoma tissue, labeling SUMO4 using ab170850 at a 1/50 dilution, followed by peroxidase-conjugation of the secondary antibody and DAB staining.
Western blot - Anti-SUMO4 antibody (ab170850)
Anti-SUMO4 antibody (ab170850) at 1/100 dilution + HepG2 cell line lysate at 35 µg